Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Rating of “Moderate Buy” from Brokerages

Intensity Therapeutics Inc. (NASDAQ:INTS) has been given a consensus rating of “Moderate Buy” by the four analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $37.50.

Several research firms recently issued reports on INTS. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings cut Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th.

Institutional Trading of Intensity Therapeutics

Several large investors have recently modified their holdings of INTS. Mesirow Financial Investment Management Inc. grew its stake in shares of Intensity Therapeutics by 81.8% in the third quarter. Mesirow Financial Investment Management Inc. now owns 200,000 shares of the company’s stock worth $49,000 after purchasing an additional 90,000 shares during the last quarter. Legacy Advisors LLC bought a new stake in shares of Intensity Therapeutics in the fourth quarter worth about $63,000. Geode Capital Management LLC grew its stake in shares of Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after purchasing an additional 201,357 shares during the last quarter. Jane Street Group LLC purchased a new stake in Intensity Therapeutics in the fourth quarter worth about $26,000. Finally, State Street Corp lifted its holdings in Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after buying an additional 121,700 shares during the period. 3.74% of the stock is owned by institutional investors.

Intensity Therapeutics Price Performance

Shares of NASDAQ:INTS opened at $3.92 on Monday. The stock’s 50-day moving average price is $4.67 and its 200-day moving average price is $7.29. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50. The stock has a market capitalization of $10.58 million, a P/E ratio of -0.69 and a beta of 2.78. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. On average, equities analysts anticipate that Intensity Therapeutics will post -2.7 earnings per share for the current year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.